Abstract
Background Neuropsychiatric symptoms in Parkinson’s disease (PD) may increase dementia (PDD) risk. The predictive value of these symptoms, however, has not been compared to clinical and demographic predictors of future PDD.
Methods 325 PD participants completed baseline neuropsychiatric and MDS-Task Force Level II assessments. Of these, 195 non-demented individuals were followed-up over a four-year period to detect conversion to PDD; 51 developed PDD. ROC analysis tested associations between baseline neuropsychiatric symptoms and conversion to PDD. The probability of developing PDD was also modelled as a function of neuropsychiatric inventory (NPI) total score, PD Questionnaire (PDQ) hallucinations, PDQ anxiety and contrasted to cognitive ability, age and motor function. Leave-one-out information criterion was used to evaluate which models provided useful information when predicting future PDD.
Results The PDD group experienced greater levels of neuropsychiatric symptoms compared to the PD-MCI and PD-N groups at baseline. Few differences were found between the PD-MCI and PD-N groups. Five neuropsychiatric measures were significantly, but weakly, associated with future PDD. The strongest was NPI total score: AUC=0.66 [0.55-0.76]. There was, however, no evidence that it contained useful out-of-sample predictive information of future PDD (delta ELPD=1.6 (SD 2.4)); Similar results held for PDQ hallucinations and PDQ anxiety. In contrast, cognitive ability (delta ELPD=35 (SD 8)) and age (delta ELPD=11 (SD 5)) provided useful predictive information of future PDD.
Conclusions Cognitive ability and age strongly out-performed neuropsychiatric measures as markers of developing PDD within four years. Therefore, neuropsychiatric symptoms do not appear to be useful markers of PDD risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We would like to acknowledge funding from the New Zealand Health Research Council, Brain Research New Zealand-Rangahau Roro Aotearoa, University of Otago, University of Canterbury, Neurological Foundation of New Zealand, Canterbury Medical Research Foundation, and the New Zealand Brain Research Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Health and Disability Ethics Committee of the New Zealand Ministry of Health
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos